Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/alt-funding

Funding Opportunities for Test Method Developers

NICEATM and ICCVAM seek to facilitate development of test methods that replace, reduce, and refine the use of animals in testing. In addition, both organizations are committed to the protection of human health, animal health, and the environment. This page lists announcements of funding opportunities intended to support the development of alternative test methods. If you are aware of a funding opportunity that could be included on this page, please contact NICEATM.

On April 17, 2020, NIEHS SBIR/STTR program in coordination with NICEATM presented a webinar-based town hall meeting, "Development of New Approach Methodologies to Reduce Animal Use in Toxicity Testing." View presentations >>
SBIR and STTR Omnibus Grant Solicitations of the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration

NIEHS is offering funding for small businesses developing technologies of interest to the Tox21 program. These technologies include:

  • Improved or expanded testing methods for toxicity screening
  • Computational approaches for predictive toxicology
  • Technologies such as alternative or improved methods for fixing and preserving tissues

The funding is being offered as part of the 2019 Omnibus Solicitation of the NIH, CDC, and Food and Drug Administration. This funding is available for small business grant applications to support development and commercialization of innovative technologies. View more information on the NIEHS website.

SBIR/STTR Omnibus Solicitations and Accompanying Resources

Next due date: September 5, 2020

For more information about this opportunity, contact:

NIH Funding Resources

The NIEHS SBIR/STTR Program Staff encourages applicants to submit grants at least one week before the deadline and to take advantage of the following resources:

HESI to Support Development of Cardiac Safety Assays; Letters of Intent Due June 8

HESI is seeking proposals for studies to develop human-relevant, mechanism-based assays evaluating cardiac safety liabilities. Assays should focus on any of six failure modes:

  • Changes in blood pressure or heart rate
  • Changes in contractility and ejection fraction
  • Electrophysiology
  • Cardiac cell injury
  • Valvular injury or proliferation
  • Hemorrhage and coagulation

Awards of up to $50,000 will be awarded for 12-month projects. Awardees must be based in the United States. Letters of intent are due June 8. 

NCATS Funding Use of Tissue Chips to Support COVID-19 Research

NCATS has issued two Notices of Special Interest to support research in collecting and examining data on the risks and outcomes for COVID-19 infections using MPS or tissue chips. Such work is expected to advance the translation of research findings into diagnostics, therapeutics, and vaccines. Applications for both opportunities will be accepted on a rolling basis from May 15, 2020, through January 25, 2022.

  • NOT-TR-20-016 announces the availability of one-year administrative supplements for investigators and institutions funded through existing grants of the NCATS MPS program. Proposals should address how the work will contribute to advancing translational research for COVID-19. 
  • NOT-TR-20-017 announces the availability of competitive revisions for investigators and institutions funded through existing grants of the NCATS MPS program. Proposals should address development of MPS models for COVID-19, the use of MPS for rapid detection of COVID-19 infection, or the use of MPS to evaluate potential therapeutics for COVID-19.